Upfront treatment with the combination of doxorubicin and sorafenib (Nexavar) did not improve overall survival (OS) compared with sorafenib alone for patients with advanced hepatocellular carcinoma (HCC). Additionally, the combination was associated with increased toxicity, according to results from the phase III CALGB 80802 trial presented at the 2016 ASCO Annual Meeting.
Read more here.
Reference:
Abou-Alfa GK, Niedzwieski D, Knox JJ, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol. 2016;34 (suppl; abstr 4003).
No comments:
Post a Comment